ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE

August 27, 2019

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

Actero, Sponsor of the 9th International Radio-Oncology Congress

March 11, 2025

Author:

Acteropharma

From January 30 to February 1, the 9th International Radio-Oncology Congress was held with the aim of advancing scientific programs in the community and supporting the expansion of cancer research.

Welcoming Nowruz with “Kindness and Generosity”

March 5, 2025

Author:

Acteropharma

For several years, in a commendable initiative aligned with this national tradition, March 4 has been designated as the National Day of Kindness and Generosity in our country’s official calendar.

Men’s Health Cup (Dec 2024)

January 18, 2025

Author:

Acteropharma

On the occasion of Movember and with the aim of raising awareness about men’s health, Actero organized a futsal tournament among pharmacies. This sports event, known as the “Men’s Health Cup,” saw widespread participation from various teams across the country and successfully highlighted the importance of men’s health issues.